Lance v. Wyeth: A New Cause of Action in Pennsylvania?

Issuing an opinion over two years after oral argument, the Pennsylvania Supreme Court ruled last week in Lance v. Wyeth that pharmaceutical companies can be held liable for negligence in the design and marketing of drugs. While the 4-2 majority opinion stated that Wyeth was asking for the court to impose “a new [restricted] duty regime” by ruling against such negligence claims, this decision actually expands the duty regime by allowing them.

BACKGROUND -

In April 1996, the Food and Drug Administration (“FDA”) approved Redux as a prescription weight-loss drug. The Redux packaging warned of an increased risk of pulmonary hypertension (“PPH”). By September 1997, Wyeth and the FDA announced that the drug would no longer be available in the United States following reports of an association between the medication and serious heart problems.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Drug Manufacturers, Manufacturing Defects, Marketing, Negligence, Prescription Drugs, Wyeth

Published In: Civil Procedure Updates, Consumer Protection Updates, Personal Injury Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Morrison & Foerster LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »